Back to search
FDAFDA · Food and drugs·Recall number D-0087-2022

Irbesartan Tablets USP, 150 mg a) 30 count (NDC 68180-411-06) and b) 90 count (NDC 68180-411-09) bottles, Rx only

Published November 10, 2021 · Recall initiated: October 12, 2021

Summary

FDA records drug Class II recall D-0087-2022, published November 10, 2021 and initiated October 12, 2021. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 134,016 bottles; Lot: a) Lot# H804403, exp. date 31/08/2021 H805251, exp. date 30/11/2021 H805640, exp. date 30/11/2021 H901580; exp. date 30/04/2022 b) Lot# H804492, exp. date 31/08/2021 H805252, exp. date 30/11/2021 H805253, exp. date30/11/2021 H805641, exp. date30/11/2021 H805642, exp. date30/11/2021 H805643, exp. date 30/11/2021 H901581, exp. date 30/04/2021 H902139, exp. date 30/04/2022 H902140, exp. date 30/04/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: impurity N-nitrosoirbesartan detected in API

What to do

Voluntary: Firm initiated · Letter

Get an email if IRBESARTAN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
IRBESARTAN
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Product was distributed to major distributors who may have further distributed the product nationwide.
Lot
a) Lot# H804403, exp. date 31/08/2021 H805251, exp. date 30/11/2021 H805640, exp. date 30/11/2021 H901580; exp. date 30/04/2022 b) Lot# H804492, exp. date 31/08/2021 H805252, exp. date 30/11/2021 H805253, exp. date30/11/2021 H805641, exp. date30/11/2021 H805642, exp. date30/11/2021 H805643, exp. date 30/11/2021 H901581, exp. date 30/04/2021 H902139, exp. date 30/04/2022 H902140, exp. date 30/04/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Irbesartan Tablets USP, 150 mg a) 30 count (NDC 68180-411-06) and b) 90 count (NDC 68180-411-09) bottles, Rx only recalled?

Yes. FDA published recall D-0087-2022 on November 10, 2021. Reported hazard: CGMP Deviations: impurity N-nitrosoirbesartan detected in API

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: IRBESARTAN.